Thalys Medical Technology Group SHSE:603716 株式レポート Thalys Medical Technology Group Corporation
SHSE:603716 株式レポート
603716 株式概要 タリス医療技術グループ株式会社は、中国で医療検査の集中的な運用サービスを提供しています。
Thalys Medical Technology Group Corporation 競合他社 価格と性能
の歴代最高値、変動、値下がりまとめThalys Medical Technology Group 過去の株価 現在の株価 CN¥8.45 52週高値 CN¥13.10 52週安値 CN¥5.13 ベータ 0.76 11ヶ月の変化 19.35% 3ヶ月変化 24.82% 1年変化 -28.21% 33年間の変化 -42.91% 5年間の変化 -50.61% IPOからの変化 -23.68%
最新ニュース
Third quarter 2024 earnings released: CN¥0.42 loss per share (vs CN¥0.033 loss in 3Q 2023) Oct 29
Wuhan Herun Ruihui Business Consulting Co., Ltd. agreed to acquire 80% stake in Wuhan Huixin Technology Development Co., Ltd. from Thalys Medical Technology Group Corporation (SHSE:603716) for CNY 72 million. Oct 02
Thalys Medical Technology Group Corporation to Report Q3, 2024 Results on Oct 29, 2024 Sep 30
Thalys Medical Technology Group Corporation (SHSE:603716) Surges 28% Yet Its Low P/S Is No Reason For Excitement Aug 12
Thalys Medical Technology Group Corporation to Report First Half, 2024 Results on Aug 30, 2024 Jun 28 Thalys Medical Technology Group Corporation (SHSE:603716) announces an Equity Buyback for CNY 20 million worth of its shares. Jun 06
最新情報をもっと見る
Third quarter 2024 earnings released: CN¥0.42 loss per share (vs CN¥0.033 loss in 3Q 2023) Oct 29
Wuhan Herun Ruihui Business Consulting Co., Ltd. agreed to acquire 80% stake in Wuhan Huixin Technology Development Co., Ltd. from Thalys Medical Technology Group Corporation (SHSE:603716) for CNY 72 million. Oct 02
Thalys Medical Technology Group Corporation to Report Q3, 2024 Results on Oct 29, 2024 Sep 30
Thalys Medical Technology Group Corporation (SHSE:603716) Surges 28% Yet Its Low P/S Is No Reason For Excitement Aug 12
Thalys Medical Technology Group Corporation to Report First Half, 2024 Results on Aug 30, 2024 Jun 28 Thalys Medical Technology Group Corporation (SHSE:603716) announces an Equity Buyback for CNY 20 million worth of its shares. Jun 06
Thalys Medical Technology Group Corporation, Annual General Meeting, May 20, 2024 Apr 29
First quarter 2024 earnings released: EPS: CN¥0.02 (vs CN¥0.07 loss in 1Q 2023) Apr 28
Thalys Medical Technology Group Corporation, Annual General Meeting, May 20, 2024 Apr 28
Thalys Medical Technology Group Corporation to Report Q1, 2024 Results on Apr 27, 2024 Mar 29 An undisclosed buyer acquired 51% stake in Shanxi Thalys Medical Technology Co., Ltd. from Thalys Medical Technology Group Corporation (SHSE:603716) for CNY 1.53 million.
Thalys Medical Technology Group Corporation (SHSE:603716) announces an Equity Buyback for CNY 20 million worth of its shares. Feb 08
Thalys Medical Technology Group Corporation to Report Fiscal Year 2023 Results on Apr 27, 2024 Dec 29
New major risk - Financial position Oct 27
Second quarter 2023 earnings released: EPS: CN¥0.084 (vs CN¥0.099 loss in 2Q 2022) Aug 30
New minor risk - Share price stability Aug 10
Thalys Medical Technology Group Corporation to Report First Half, 2023 Results on Aug 30, 2023 Jun 28
First quarter 2023 earnings released: CN¥0.07 loss per share (vs CN¥0.10 profit in 1Q 2022) Apr 28
Less than half of directors are independent Nov 16
Third quarter 2022 earnings released: CN¥0.016 loss per share (vs CN¥0.012 loss in 3Q 2021) Oct 27
Second quarter 2022 earnings released: CN¥0.099 loss per share (vs CN¥0.012 loss in 2Q 2021) Aug 17
Huang Jianfeng completed the acquisition of Thalys Medical Technology Group Inc. (SHSE:603716) from Saihai (Shanghai) Health Technology Co., Ltd. Aug 12
Full year 2021 earnings: EPS and revenues exceed analyst expectations Apr 27
Less than half of directors are independent Apr 27
Second quarter 2021 earnings released: CN¥0.012 loss per share (vs CN¥0.18 profit in 2Q 2020) Aug 25
Investor sentiment improved over the past week Jun 05
First quarter 2021 earnings released: EPS CN¥0.03 (vs CN¥0.12 loss in 1Q 2020) Apr 30
New 90-day low: CN¥14.45 Feb 03
New 90-day low: CN¥14.50 Jan 14
New 90-day high: CN¥17.71 Dec 16
New 90-day low: CN¥14.70 Nov 02
Third quarter earnings released Oct 30
Thalys Medical Technology Group Inc. to Report Q3, 2020 Results on Oct 30, 2020 Oct 29
New 90-day high - CN¥18.10 Sep 14
First half earnings released Aug 21
Thalys Medical Technology Inc. (SHSE:603716) agreed to acquire remaining 49% stake in Shanghai Thalys Medical Technology Co., Ltd. from Liu Hongkui and Zhang Luqi for CNY 0. Aug 06
New 90-day high - CN¥17.33 Jul 29 株主還元 603716 CN Biotechs CN 市場 7D 15.4% 6.9% 6.9% 1Y -28.2% -11.4% 10.3%
株主還元を見る
業界別リターン: 603716過去 1 年間で-11.4 % の収益を上げたCN Biotechs業界を下回りました。
リターン対市場: 603716は、過去 1 年間で10.3 % のリターンを上げたCN市場を下回りました。
価格変動 Is 603716's price volatile compared to industry and market? 603716 volatility 603716 Average Weekly Movement 8.2% Biotechs Industry Average Movement 8.7% Market Average Movement 7.9% 10% most volatile stocks in CN Market 12.2% 10% least volatile stocks in CN Market 5.4%
安定した株価: 603716過去 3 か月間に大きな価格変動はありませんでした。
時間の経過による変動: 603716の 週次ボラティリティ ( 8% ) は過去 1 年間安定しています。
会社概要 タリス・メディカル・テクノロジー・グループ株式会社は、中国で医療検査の集中運営サービスを提供している。同社は以前はタリス・メディカル・テクノロジー株式会社として知られていたが、2020年9月にタリス・メディカル・テクノロジー・グループ株式会社に社名を変更した。Thalys Medical Technology Group Inc.は2004年に設立され、中国の武漢に本社を置いている。
もっと見る Thalys Medical Technology Group Corporation 基礎のまとめ Thalys Medical Technology Group の収益と売上を時価総額と比較するとどうか。 603716 基礎統計学 時価総額 CN¥1.58b 収益（TTM） -CN¥210.78m 売上高(TTM ) CN¥1.90b
収益と収入 最新の決算報告書（TTM）に基づく主な収益性統計 603716 損益計算書（TTM） 収益 CN¥1.90b 売上原価 CN¥1.54b 売上総利益 CN¥357.14m その他の費用 CN¥567.92m 収益 -CN¥210.78m
一株当たり利益（EPS） -1.13 グロス・マージン 18.83% 純利益率 -11.11% 有利子負債／自己資本比率 96.1%
603716 の長期的なパフォーマンスは？
過去の実績と比較を見る
Simply Wall St™ Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
{"enabled":true,"variant":{"name":"display-ssr-flag","enabled":true,"feature_enabled":true,"featureEnabled":true},"flagsReady":true,"flagsError":null}
